TWST:NASDAQTwist Bioscience Corporation Analysis

Twist Bioscience (TWST) is trading at $59.53, comfortably above its 20‑day ($57.69), 50‑day ($51.21) and 200‑day ($37.79) simple moving averages, signaling a bullish price backdrop. The RSI sits near 57, indicating modest momentum, while the MACD histogram is negative and the signal line is bearish, suggesting short‑term pressure near the $66.06 resistance level. The stock’s beta of 2.4 and 30‑day volatility of roughly 74% underscore a highly volatile, high‑beta profile.
Fundamentally, TWST posted 19% revenue growth with a solid 52% gross margin, yet it remains unprofitable with a -35% operating margin and negative free cash flow, and carries $110 M of debt against $172 M of cash. Valuation multiples are stretched (P/B ~8×, price‑to‑sales ~9×) relative to peers, and the company does not pay a dividend. Analyst sentiment is bullish (strong‑buy) and the firm is slated to release its Q2 2026 results on May 4, which could act as a catalyst.